RATIONAL THERAPY FOR VULVOVAGINAL CANDIDIASIS IN PREGNANT WOMEN

Objective. To evaluate the efficacy and tolerability of livarol used to treat acute vulvovaginal candidiasis (VVC) in pregnant women. Subjects and methods. Sixty-two pregnant women with VVC were followed up. Thirty-two patients received livarol (a study group) and 30 took pimafucin (a control group). Examinations were made before, 1 week and 2 months after the termination of treatment, and 6 weeks after delivery. The vaginal microflora was examined by microscopic and culture techniques. Results. After 2 months of livarol therapy, the clinical symptoms of VVC completely disappeared and the vaginal microbial environment became normal in 96.9% of the patients in the study group while only 66.7% of the control patients achieved a positive result (p<0.005). Recurrent VVC was observed in 3.1 and 33.3% in the study and control groups, respectively. The timely use of livarol made it possible to avoid the early development of neonatal upper airway diseases; and no recurrences — just 2 months after delivery — enabled the use of coils. Conclusion. Livarol is effective and safe for the treatment of VVC in pregnant women.

vulvovaginal candidiasis, pregnancy, livarol